Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)

Cited by (322)

Items 101–200 of 322

1. Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases
   Diego Márquez-Medina, Sanjay Popat · 2015 · Clinical & Translational Oncology
2. Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis
   Ji Wang, Chengchu Zhu · 2016 · OncoTargets and Therapy
3. SABR for aggressive local therapy of metastatic cancer: A new paradigm for metastatic non-small cell lung cancer
   Kenneth D. Westover, Puneeth Iyengar, Akanksha Sharma, Robert D Timmerman · 2015 · Lung Cancer
4. Second-Line Chemotherapy and Beyond for Non–Small Cell Lung Cancer
   Greg Andrew Durm, Nasser H. Hanna · 2016 · Hematology/Oncology Clinics of North America
5. Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
   Michael S. Gordon, John J. Nemunaitis, Minal A. Barve, Zev A. Wainberg, Erika Paige Hamilton, Ramesh K. Ramanathan, George W. Sledge, Huibin Yue, Susan E. Morgan-Lappe, Martha Elizabeth Blaney et al. · 2021 · Molecular Cancer Therapeutics
6. Malignant neoplasm of the bronchi and lung: Russian clinical guidelines
   Константин Константинович Лактионов, Елена Владимировна Артамонова, Tatiana N. Borisova, Бредер Валерий Владимирович, Бычков Юрий Маркович, Liubov Yu Vladimirova, Nikita Volkov, Степан Мкртычевич Ергнян, A.S. Zhabina, Pavel V. Kononets et al. · 2021 · Journal of Modern Oncology
7. Bevacizumab-Based Therapies in Malignant Tumors—Real-World Data on Effectiveness, Safety, and Cost
   Elena Chitoran, Vlad Rotaru, Sinziana Octavia Ionescu, Aisa Gelal, Cristina Mirela Capsa, Roxana Elena Bohîlțea, Mădălina-Nicoleta Mitroiu, Dragoş Şerban, Giuseppe Gullo, Daniela-Cristina Stefan et al. · 2024 · Cancers
8. Incorporation of Antiangiogenic Therapy Into the Non–Small-Cell Lung Cancer Paradigm
   Benjamin F. Chu, Gregory A. Otterson · 2016 · Clinical Lung Cancer
9. Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
   Laurent Greillier, Pascale Tomasini, Fabrice Barlési · 2016 · Therapeutic Advances in Respiratory Disease
10. Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy
    Andrea Rocca, Daniele Andreis, Anna Fedeli, Roberta Maltoni, Samanta Sarti, Lorenzo Cecconetto, Elisabetta Pietri, Alessio Schirone, Sara Bravaccini, Patrizia Serra et al. · 2015 · Expert Opinion on Drug Metabolism & Toxicology
11. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non–Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
    Oliver Pascal Gautschi, Nicholas Mach, Sacha I. Rothschild, Qiyu Li, Rolf Arno Stahel, Alfred Zippelius, Richard L. Cathomas, Martin Früh, Daniel C. Betticher, Solange Peters et al. · 2015 · Clinical Lung Cancer
12. Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study
    Roberto Petrioli, Edoardo Francini, Anna Ida Fiaschi, Letizia Laera, Luca Luzzi, Piero Paladini, Claudia Ghiribelli, Luca Voltolini, Vincenzo Bianco, Giandomenico Roviello · 2015 · Medical Oncology
13. Targeting the immune system to treat lung cancer: rationale and clinical experience
    Nicolas Marie Guibert, Myriam Delaunay, Julien Mazières · 2015 · Therapeutic Advances in Respiratory Disease
14. NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer
    David S. Ettinger, Sidney Kimmel, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thierry Marie Jahan et al. · 2014
15. Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Xingsheng Hu, Ke Pu, Xuqin Feng, Shimin Wen, Xi Bo Fu, Cuihua Guo, Wenwu He · 2016 · PLoS ONE
16. Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer
    Michele M. Spence, Rita L. Hui, Jennifer T. Chang, Joanne E. Schottinger, Mirta Millares, Nazia Rashid · 2017 · Journal of Managed Care & Specialty Pharmacy
17. Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer
    Victor Ho-Fun Lee, Tony S.K. Mok, Yasushi Goto, V.C.C. Hsue, Yang Li, Y. Jiang, Dennis Kwok Chuen Leung, K.S. Lau, Philip Yat Hang Tse · 2019 · Clinical Oncology
18. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer
    Tania Losanno, Antônio Rossi, Paolo Maione, Alba Napolitano, Cesare Gridelli · 2016 · Expert Opinion on Biological Therapy
19. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non–Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial
    David Robert Spigel, Robert M. Jotte, Santiago Ponce-Aix, Laurent Gressot, Daniel Morgensztern, Michael McCleod, Mark A. Socinski, Davey B. Daniel, Óscar Juan, Kathryn Finch Mileham et al. · 2020 · Clinical Lung Cancer
20. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0
    Joshua E. Reuss, Lyudmila A. Bazhenova, Nofisat Ismaila, Fawzi Abu Rous, Amith Ahluwalia, Krishna Chaitanya Alluri, Ibrahim Hanna Azar, Toby Campbell, Greg Andrew Durm, Jill Feldman et al. · 2026 · Journal of Clinical Oncology
21. Bevacizumab in Advanced NSCLC: Chemotherapy Partners and Duration of Use
    Ryan D. Gentzler, Sarah Elizabeth Yentz, Jyoti D. Patel · 2013 · Current Treatment Options in Oncology
22. Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion
    Motohiro Tamiya, Akihiro Tamiya, Hidekazu Suzuki, Yoshihiko Taniguchi, Kanako Katayama, Shojiro Minomo, Keiko Nakao, Naoko Takeuchi, Yoshinobu Matsuda, Yujiro Naito et al. · 2021 · Investigational New Drugs
23. Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of 14 Studies
    Shun Lü, Yongfeng Yu, Zhiwei Chen, Xiangyun Ye, Ziming Li, Xiaomin Niu · 2015 · Lung
24. Maintenance Therapy for Advanced Lung Cancer: Who, What, and When?
    David E. Gerber · 2013 · Journal of Clinical Oncology
25. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
    Yasuhiro Tsutani, Yoshihiro Miyata, Takeshi Masuda, Kazunori Fujitaka, Mihoko Doi, Yoshikazu Awaya, Shoichi Kuyama, Soichi Kitaguchi, Kazuhiro Ueda, Noboru Hattori et al. · 2018 · BMC Cancer
26. Defining Aggressive Or Early Progressing Nononcogene-Addicted Non-Small-Cell Lung Cancer: A Separate Disease Entity?
    Martin Reck, Keith M. Kerr, Christian Grohé, Christian Manegold, Nick Pavlakis, Luis G Paz-Ares, Rudolf Maria Huber, Sanjay Popat, N. Thatcher, Keunchil Park et al. · 2019 · Future Oncology
27. Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
    Benjamin K. Schneider, Arnaud Boyer, Joseph Ciccolini, Fabrice Barlési, Kenneth Wang, Sébastien Benzekry, Jonathan Paul Mochel · 2019 · CPT Pharmacometrics & Systems Pharmacology
28. Complex Decisions for First-Line and Maintenance Treatment of Advanced Wild-Type Non-Small Cell Lung Cancer
    Ryan D. Gentzler, Melissa Lynne Johnson · 2015 · The Oncologist
29. First-Line Systemic Therapy for Non–Small Cell Lung Cancer
    Rebecca Suk Heist · 2016 · Hematology/Oncology Clinics of North America
30. Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
    Andrés Felipe Cardona, Leonardo Rojas, Beatriz Wills, Oscar G. Arrieta, Hernán Carranza, Carlos Alberto Vargas, Jorge Miguel Otero, Mauricio Cuello, Luis Corrales, Claudio Marcelo Martin et al. · 2016 · PLoS ONE
31. Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non–Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care
    Jyoti D. Patel, Luis G Paz-Ares, Ralph Zinner, Fabrice Barlési, Andrew G. Koustenis, Coleman K. Obasaju · 2018 · Clinical Lung Cancer
32. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016
    Satoshi Ikeda, Terufumi Kato, Takashi Ogura, Akimasa Sekine, T. Oda, Noriyuki Masuda, Satoshi Igawa, Ken Katono, Sakiko Otani, Kouzo Yamada et al. · 2018 · BMC Cancer
33. Non-Small-Cell Lung Cancer Treatment
    Ryo Koyama, Kazuhisa Takahashi · 2016 · Juntendō Igaku/Juntendo igaku
34. Show me the roads and give me a road map: Development of a patient conversation tool to improve lung cancer treatment decision-making
    Sara E. Golden, Natalie G. Disher, Nathan F. Dieckmann, Karen Eden, Daniel D. Matlock, Kelly C. Vranas, Christopher G. Slatore, Donald Richard Sullivan · 2022 · PEC Innovation
35. Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials
    Le‐Tian Huang, Rui Cao, Yan-Ru Wang, Li Sun, Xiangyan Zhang, Yijia Guo, Jianzhu Zhao, Shuling Zhang, Wei Jing, Jun Song et al. · 2021 · BMC Cancer
36. Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study
    Xiaodong Gu, Zhiyong Shi, Lan Shao, Yuxin Zhang, Yiping Zhang, Zhengbo Song, Wenxian Wang, Guangyuan Lou · 2022 · BMC Cancer
37. Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer
    Chung‐Yu Chen, Jou‐Wei Lin, Jenq‐Wen Huang, Kuan‐Yu Chen, Jin‐Yuan Shih, Chong‐Jen Yu, Pan‐Chyr Yang · 2015 · Clinical Lung Cancer
38. Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG)
    on behalf of the HORG’s Lung Cancer Working Group, Alexios Matikas, Nikolaos K. Kentepozidis, Alexandros S Ardavanis, Michael M. Vaslamatzis, Aris Polyzos, Ch. Emmanouilides, Panagiotis Katsaounis, Filippos Koinis, Spyros Xynogalos et al. · 2016 · Cancer Chemotherapy and Pharmacology
39. ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?
    Nicolas Girard, Clarisse Audigier-Valette, Alexis Benjamin Cortot, B. Mennecier, Didier Debieuvre, David Planchard, Gérard Zalcman, Denis Moro‐Sibilot, Jacques L. Cadranel, Fabrice Barlési · 2014 · Expert Review of Anticancer Therapy
40. Polyisoprenylated Cysteinyl Amide Inhibitors Deplete K-Ras and Induce Caspase-dependent Apoptosis in Lung Cancer Cells
    Augustine T. Nkembo, Felix Amissah, Elizabeth Ntantie, Rosemary A. Poku, Olufisayo O. Salako, Offiong Francis Ikpatt, Nazarius Saah Lamango · 2019 · Current Cancer Drug Targets
41. Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules
    Jun Chen, Xin Li, Sen Wei · 2014 · OncoTargets and Therapy
42. Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study
    Seiji Niho, Yuichiro Ohe, Hironobu Ohmatsu, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Kōichi Goto · 2017 · Lung Cancer
43. Nucleic Acid‐based Electrochemical Sensors Facilitate the Study of DNA Binding by Platinum (II)‐based Antineoplastics
    Yao Wu, Netzahualcóyotl Arroyo‐Currás · 2024 · Angewandte Chemie International Edition
44. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
    Oliver Pascal Gautschi, Sacha I. Rothschild, Qiyu Li, Klazien W Matter-Walstra, Alfred Zippelius, Daniel C. Betticher, Martin Früh, Rolf Arno Stahel, Richard L. Cathomas, Daniel Rauch et al. · 2016 · Clinical Lung Cancer
45. Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer
    Masahiro Yamasaki, ISAO AKAMI, Kikuo Nakano, Mihoko Doi, Souichi Kitaguchi, Tomohiro Kondo, JOJI SAKURAI, Noboru Hattori, Ken-ichi Arita · 2017 · Anticancer Research
46. Non-small Cell Lung Cancer
    Apichat Tantraworasin, Sarawut Kongkarnka, Nirush Lertprasertsuke, Yutthaphan Wannasopha, Juntima Euathrongchit, Thatthan Suksombooncharoen, Somcharoen Saeteng, Sophon Siwachat, Busayamas Chewaskulyong · 2019 · Springer eBooks
47. Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study
    Florian Slimano, Antoine Le Bozec, Amélie Cransac, Pascal Foucher, François Lesauvage, Bertrand Delclaux, Anne Dory, B. Mennecier, Benjamin Bertrand, Marie-Christine Gubeno-Dumon et al. · 2022 · Lung Cancer
48. A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer
    Kazuhiko Yamada, Masao Ichiki, Kazuhisa Takahashi, Yasushi Hisamatsu, Hiroaki Takeoka, Koichi Azuma, Takehito Shukuya, Kazuo Nishikawa, Takaaki Tokito, Hidenobu Ishii et al. · 2016 · Cancer Chemotherapy and Pharmacology
49. Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321
    Takashi Kasai, Kiyoshi Mori, Yoichi Nakamura, Nobuhiko Seki, Yasuko Ichikawa, Haruhiro Saito, Tetsuro Kondo, Kazuo Nishikawa, Satoshi Otsu, Akihiro Bessho et al. · 2023 · Cancer Medicine
50. 2014 update on non-small cell lung cancer (excluding diagnosis)
    Valérie Gounant, Antoine Khalil, Perrine Créquit, A. Lavolé, Anne-Marie Ruppert, Martine Antoine, Bernard J. Milleron, Marie Wislez, Marie France Carette, Jalal Assouad et al. · 2014 · Diagnostic and Interventional Imaging
51. A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France
    Kaisa Taipale, Katherine B. Winfree, Mark E. Boye, Mickaël Basson, Ghassan Sleilaty, James Eaton, Rachel Evans, CHRISTOS CHOUAID · 2017 · ClinicoEconomics and Outcomes Research
52. Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer
    Seigo Minami, Takashi Kijima · 2015 · Lung Cancer Targets and Therapy
53. Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy
    Guillaume Sicard, Fréderic Fina, Raphaëlle Fanciullino, Fabrice Barlési, Joseph Ciccolini · 2020 · Pharmaceutics
54. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non‐small cell lung cancer: A meta‐analysis of randomized controlled trials
    Miaowen Liu, Nachuan Luo, Zige Fang, Qiangyun Liu, Fengming Yi, Yiping Wei, Xinyi Zhang, Wenxiong Zhang · 2021 · Journal of Clinical Pharmacy and Therapeutics
55. Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer
    Minglei Zhuo, Hua Bai, Zhijie Wang, Jianchun Duan, Tongtong An, Meina Wu, Jun Zhao, Yuyan Wang, Shuhang Wang, Jie Wang · 2014 · Molecular and Clinical Oncology
56. Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial
    David Felix Heigener, José Rodrigues Pereira, Enriqueta Felip, Juraj Mazal, Lyudmila Manzyuk, Eng Huat Tan, Ofer Merimsky, Barbara Sarholz, Regina Esser, Ulrich Gatzemeier · 2014 · Targeted Oncology
57. International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non–Small Cell Lung Cancer: Realities and Hopes
    Filippo de Marinis, Emilio Bria, Fortunato Ciardiello, Lucio Crinò, Jean-Yves Douillard, Frank Griesinger, Diether Lambrechts, Maurice Pérol, Suresh S. Ramalingam, Egbert Frederik Smit et al. · 2016 · Journal of Thoracic Oncology
58. Doublet chemotherapy with cisplatin and pemetrexed is associated with a favorable outcome in patients with advanced non-squamous non-small-cell lung cancer who are eligible for bevacizumab and maintenance therapy
    Kazuhisa Nakashima, Haruyasu Murakami, Shota Omori, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Masahiro Endo, Toshiaki Takahashi · 2016 · Molecular and Clinical Oncology
59. Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study
    Chunhua Zhou, Feng Yang, Wenjuan Jiang, Yongchang Zhang, Haiyan Yang, Liang Zeng, Li Liu, Yi Xiong, Fanxu Zeng, Zhan Wang et al. · 2021 · Frontiers in Pharmacology
60. Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
    Armando Santoro, Garrido Pilar, Daniel Shao-Weng Tan, Jon Zugazagoitia, Frances A. Shepherd, Alessandra Bearz, Fabrice Barlési, Tae Min Kim, Tobias Raphael Overbeck, Enriqueta Felip et al. · 2024 · BMC Cancer
61. The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC)
    Lingyu Ding, Kejun Liu, Zhelong Jiang, Qi Chen, Ningning Zhou, Ying Liang, Hongfei Gao, Xiangchan Hong, Haiying Wu · 2014 · Tumor Biology
62. Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non–Small Cell Lung Cancer
    Jared M. Weiss, Liza Cosca Villaruz, Jonathon J. O’Brien, Anastasia Ivanova, Carrie B. Lee, Juneko Grilley Olson, Gregory Pollack, Richard Gorman, Mark A. Socinski, Thomas E. Stinchcombe · 2015 · Clinical Lung Cancer
63. Malignant neoplasm of the bronchi and lung: Russian clinical guidelines
    Константин Константинович Лактионов, Елена Владимировна Артамонова, Tatiana N. Borisova, Valeriy Vladimirovich Breder, Бычков Юрий Маркович, Liubov Yu Vladimirova, Никита Михайлович Волков, Степан Мкртычевич Ергнян, Альбина Сергеевна Жабина, Pavel V. Kononets et al. · 2022 · Journal of Modern Oncology
64. The place of pemetrexed in the management of non-small-cell lung cancer patients
    Pascale Tomasini, Laurent Greillier, Nataliya Khobta, Fabrice Barlési · 2013 · Expert Review of Anticancer Therapy
65. La qualité de vie relative à la santé dans les essais cliniques de phase III en oncologie : de l’administration du questionnaire à l’analyse statistique
    Frédéric Fiteni, Amélie Anota, Virginie Westeel, Franck Bonnetain · 2015 · Bulletin du Cancer
66. Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation
    Kelong Han, Laurent Claret, Alan B. Sandler, Asha Das, Jin Jin, René Bruno · 2016 · BMC Cancer
67. [Chinese Expert Consensus on Antiangiogenic Drugs for Advanced Non-small Cell Lung Cancer (2019 Edition)].
    2019 · Europe PMC (PubMed Central)
68. Developing CSCO Lung Cancer Practice Guidelines Stratified by Resource Availability and Treatment Value
    Qing Hua Zhou, Yi-Long Lung Cancer Wu · 2016 · Journal of Global Oncology
69. Maintenance pemetrexed in nonsmall cell lung carcinoma: Outcome analysis from a tertiary care center
    Avinash Pandey, Deepa Susan Phillip, Vanita Noronha, Amit Joshi, Amit Janu, Nirmala Jambekar, Rajesh Kaushal, Abhishek Mahajan, Kumar Prabhash · 2015 · Indian Journal of Medical and Paediatric Oncology
70. Efficacy of cisplatin/pemetrexed with bevacizumab to treat advanced lung adenocarcinoma with different drive genes: case report and literature review
    Haiyong Wang, Hui Zhu, Li Kong, Jinming Yu · 2016 · OncoTargets and Therapy
71. A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer
    Hironori Yoshida, Young Hak Kim, Yuichi Sakamori, Hiroki Nagai, Hiroaki Ozasa, Toshihiko Kaneda, Hiroshige Yoshioka, Hiroaki Nakagawa, Keisuke Tomii, Asuka Okada et al. · 2020 · Anticancer Research
72. Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open- label phase 2 study (CLEAR)
    Hibiki Udagawa, Eri Sugiyama, Toshiyuki Harada, Shinji Atagi, Ryo Koyama, Satoshi Watanabe, Yukiko Nakamura, Daijiro Harada, Osamu Hataji, Fumihiro Tanaka et al. · 2021 · Translational Lung Cancer Research
73. An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer
    Sara Pilotto, Silvia Novello, Umberto Peretti, Stefania Kinspergher, Ludovica Ciuffreda, Michèle Milella, Luisa Carbognin, Tiziana Vavalà, Roberto Ferrara, Mario Caccese et al. · 2015 · Expert Opinion on Investigational Drugs
74. A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC)
    Rencui Quan, Jiaxing Huang, Nan Chen, Wenfeng Fang, Zhihuang Hu, Jianhua Zhan, Ting Zhou, Li Zhang, Hongyu Zhang · 2016 · Tumor Biology
75. Long-term complete response to carboplatin plus paclitaxel combined with bevacizumab in a patient with metastatic spindle cell carcinoma
    Shinya Sakata, Sho Saeki, Ryo Sato, Shiho Ishizuka, Jiichiro Sasaki, Kazuhiko Fujii · 2017 · Respiratory Investigation
76. Analysis of bevacizumab treatments and metastatic sites of lung cancer
    Hideomi Sato, Hiromi Nagashima, Masachika Akiyama, Takashi Ito, Tatsuya Hashimoto, Hirotaka Saikawa, Yu Utsumi, Makoto Maemondo · 2020 · Cancer Treatment and Research Communications
77. Treatment paradigms in advanced non-small-cell lung cancer.
    Caroline Elizabeth McCoach, Karen L. Kelly · 2013 · PubMed
78. The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Feiyu Shan, Bo Zhang, Leitao Sun, Lufan Xie, Minhe Shen, Shanming Ruan · 2018 · BioMed Research International
79. The vertebral 3′-deoxy-3′-18F-fluorothymidine uptake predicts the hematological toxicity after systemic chemotherapy in patients with lung cancer
    Yukihiro Umeda, Tetsuya Tsujikawa, Masaki Anzai, Miwa Morikawa, Yuko Waseda, Maiko Kadowaki, Hiroko Shigemi, Shingo Ameshima, Tetsuya Mori, Yasushi Kiyono et al. · 2019 · European Radiology
80. Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients
    Zhehai Wang, Ning Tang · 2016 · OncoTargets and Therapy
81. Overall Survival and Safety With Pemetrexed/Platinum ± Anti-VEGF Followed by Pemetrexed ± Anti-VEGF Maintenance in Advanced Nonsquamous Non–Small-Cell Lung Cancer: A Pooled Analysis of 4 Randomized Studies
    Edward B. Garon, Patrick M. Peterson, Maria Teresa Rizzo, Jong Seok Kim · 2021 · Clinical Lung Cancer
82. A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancer
    Ke-Jun Liu, Haiying Wu · 2015 · Oncotarget
83. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG)
    Athanasios Panayotis Kotsakis, Nikolaos K. Kentepozidis, Ch. Emmanouilidis, Aris Polyzos, Athina Agelidou, Michael M. Vaslamatzis, Vassilios Chandrinos, Sofia Agelaki, L. Vamvakas, Kostas Kalbakis et al. · 2015 · Lung Cancer
84. Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
    Normand Blais, Vera Hirsh · 2014 · Frontiers in Oncology
85. Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non–small Cell Lung Cancer Xenograft Models
    Nobuyuki Ishikura, MIEKO YANAGISAWA, Mariko Noguchi‐Sasaki, TOSHIKI IWAI, Keigo Yorozu, Mitsue Kurasawa, Masamichi Sugimoto, Kaname Yamamoto · 2017 · Anticancer Research
86. Lung adenocarcinoma with tumor resolution and dystrophic calcification after salvage surgery following immune checkpoint inhibitor therapy: A case report
    Toshiyuki Sumi, Hirofumi Uehara, 俊明 正岡, Makoto Tada, Yoshiko Keira, Koki Kamada, Naoki Shijubou, Yuichi Yamada, Hisashi Nakata, Yuji Mori et al. · 2020 · Thoracic Cancer
87. PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study
    Zhe Huang, Chunhua Zhou, Yi Xiong, Feng Yang, Fanxu Zeng, Wenjuan Jiang, Yongchang Zhang, Haiyan Yang, Li Liu, Liang Zeng et al. · 2022 · Frontiers in Oncology
88. Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib
    Parneet Kaur Cheema, Alia Thawer, J. Leake, Susanna Yee-Shan Cheng, Suneil Kumar Khanna, J. Charles Victor · 2018 · Supportive Care in Cancer
89. The role of maintenance therapy in the treatment of elderly non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials
    Liangzhe Zhang, Shugeng Gao, Jie He · 2017 · Drug Design Development and Therapy
90. Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population
    Goyal Pankaj, Ullas Batra, Dinesh Chandra Doval, Parveen Jain, Upadhyay Kumar Amitabh, Prasanta Kumar Dash, Jain Akhil, Agarwal Mohit, Rajat Bajaj · 2016 · South Asian Journal of Cancer
91. Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer
    Toshirou Fukushima, Yuuki Wakatsuki, Takashi Kobayashi, Kei Sonehara, Kazunari Tateishi, Manabu Yamamoto, Takeshi Masubuchi, Fumiaki Yoshiike, Kazuya Hirai, Tsutomu Hachiya et al. · 2018 · Cancer Chemotherapy and Pharmacology
92. Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study
    Xin Li, Jie Huang, Yao Qiu, Qianyun Zhang, Shao‐Yu Yang, Kan Wu, Jiaoli Wang, Limin Wang, Jian Ye, Shenglin Ma et al. · 2021 · Frontiers in Pharmacology
93. Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer
    Ying Kong, Hong Liang, Xiaocheng Xu, Jia Hui Xu · 2021 · Medicine
94. [Anti-angiogenesis in Lung Cancer: Current Situation, Progress and Confusion].
    Jiang Zhou, Jianhua Chen · 2022 · PubMed Central
95. Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial
    Akira Nakao, Junji Uchino, Fumiyasu Igata, Rintaro On, Takato Ikeda, Hiroshi Yatsugi, Ryosuke Hirano, T Sasaki, Keiko Tanimura, Tatsuya Imabayashi et al. · 2018 · Investigational New Drugs
96. An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer
    Kyoichi Kaira, Hisao Imai, Ryousuke Souma, REIKO SAKURAI, Yosuke Miura, Noriaki Sunaga, Norimitsu Kasahara, Yusuke Tsukagoshi, Yasuhiko Koga, Shinsuke Kitahara et al. · 2019 · Anticancer Research
97. Disease control in patients with non‐small cell lung cancer using pemetrexed: Investigating the best treatment strategy
    Yutaka Takahara, Ryudai Abe, Sumito Nagae, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Kazuaki Nishiki, Masafumi Nojiri, Ryo Kato et al. · 2024 · Thoracic Cancer
98. Quality of Life in Patients with NSCLC Receiving Maintenance Therapy
    Achim Rittmeyer · 2015 · Cancers
99. Bevacizumab in Non-small Cell Lung Cancer: An Overview of Practice in the Era of Molecular Testing
    M. Snee · 2014 · Clinical Oncology
100. Efficacy and toxicities of combination maintenance therapy in the treatment of advanced non-small-cell lung cancer: an up-to-date meta-analysis
     Jianming Hu, Jiawei Hu, Xiaolan Liu, Long Li, Xue Bai · 2019 · Bioscience Reports